The vice president and head of Alzheimer’s Disease, Dementia, and Movement Disorders in Late Stage Clinical Development at Biogen spoke about the upcoming TANGO II trial in Alzheimer disease.
“Essentially what we’re aiming to do is see if BIIB092 has an effect on symptoms in Alzheimer disease.”
Samantha Budd Haeberlein, PhD, the vice president and head of Alzheimer’s Disease, Dementia, and Movement Disorders in Late Stage Clinical Development at Biogen spoke with NeurologyLive at the Alzheimer’s Association International Conference held in Chicago, Illinois, about the TANGO II trial in Alzheimer disease.
The phase II trial is set to evaluate the safety and tolerability of BIIB092, an investigational therapy, in a goal of 528 participants with mild cognitive impairment (MCI) due to Alzheimer disease or mild AD. Additionally, the trial will assess the efficacy of a group of 3 doses of BIIB092—high, medium, and low—in slowing cognitive and functional impairment in participants. Patients will be randomized into 1 of the following 4 arms:
She also noted that the dive into biomarkers to better understand which patients might respond best to BIIB092—an entirely new area of interest for Biogen. Haeberlein also discussed how in phase I, the therapy bound itself to tau proteins, reducing the tau levels by a significant amount in the cerebral spinal fluid, a promising sign as it moves into larger and later phase testing.